急诊室的过敏删除标签计划的实施和影响
急诊室中过敏的删除标签计划的实施和影响:de-Label计划扩展
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G1X8
- Monica Caldeira-Kulbakas
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
接受健康志愿者
描述
纳入标准:
- 所有1个月至18岁的儿科患者都符合据报道的病人,符合该研究的过敏病史部分的资格。
排除标准:
- 父母/监护人和/或患者无法同意或同意。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Eligible for study risk assessment questionnaire
First, a systematic allergy risk assessment tool will enable stratification of patients' reported symptoms as (1) low risk (eg, isolated urticarial, maculopapular rash, gastrointestinal symptoms) or (2) high risk (eg, anaphylaxis, severe systemic reactions).
Only patients classified low risk will be eligible for oral provocation challenge for allergy delabeling.
Patients' ineligible for oral provocation challenge because of history of high-risk allergy symptoms or presence of clinical confounders for oral provocation challenge (eg, uncontrolled asthma) will be referred to the SickKids allergy clinic for further evaluation.
|
In the first component of the study, research staff will survey patients for history pertinent to their beta-lactam allergy label. This includes questions regarding any prior evaluations, patients' perception of their allergy label, and clinical details of allergy history. The latter involves an allergy history risk assessment, which will screen patient for high-risk features (eg, new maculopapular rash within 2 hours of administering antibiotic). Presence of any high-risk features will disqualify the patient from subsequent study components. Finally, the questionnaire will screen for presence of any clinical confounders that would preclude administration of the oral provocation challenge (eg, use of antihistamines within prior 72 hours). |
|
实验性的:Eligible for oral challenge in the emergency department
A subset of patients screened with the risk assessment questionnaire will fulfill eligibility criteria to undergo the Oral provocation challenge.
Specifically, these will be patients who (1) fulfill several procedural requirements (eg, parent able to observe child for 1 hour after oral provocation challenge), (2) have a previously unevaluated allergy label without high-risk features and without any clinical confounders for the oral provocation challenge, and (3) meet other clinical criteria for oral provocation challenge (eg, vital signs within normal range).
These participants will be given a one-time dose of Amoxicillin 17 mg/kg (maximum, 500 mg) and observed for 1 hour for a reaction.
|
In the first component of the study, research staff will survey patients for history pertinent to their beta-lactam allergy label. This includes questions regarding any prior evaluations, patients' perception of their allergy label, and clinical details of allergy history. The latter involves an allergy history risk assessment, which will screen patient for high-risk features (eg, new maculopapular rash within 2 hours of administering antibiotic). Presence of any high-risk features will disqualify the patient from subsequent study components. Finally, the questionnaire will screen for presence of any clinical confounders that would preclude administration of the oral provocation challenge (eg, use of antihistamines within prior 72 hours).
Prospective cohort study of patients presenting to the emergency department with a reported beta-lactam allergy.
(1) Allergy history and risk assessment, (2) Oral provocation challenge (if eligible), and (3) Post-discharge follow-up (if received oral provocation challenge or referred to allergy).
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The primary outcome will be the proportion of patients delabeled among those given the oral provocation challenge.
大体时间:Up to 2 weeks
|
In the primary analysis, successful beta-lactam allergy removal will be defined as tolerating oral provocation challenge without any immediate adverse reaction.
|
Up to 2 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
据报道BLA的患者比例低(潜在影响)
大体时间:第一天
|
这包括有关任何先前评估的问题,患者对过敏标签的看法以及过敏病史的临床细节。 后者涉及过敏病史的风险评估,该评估将筛查患者的高风险特征(例如,在抗生素后2小时内,新的大绝语皮疹)。 任何高风险特征的存在将使患者从随后的研究组件中取消资格。 最后,问卷将筛选出任何临床混杂因素的存在,这些混杂因素将阻止OPC的给药(例如,在72小时内使用抗组胺药)。 |
第一天
|
|
在没有任何不良反应的情况下成功划定的患者比例(直接或延迟2周)
大体时间:长达2周
|
成功的BLA去除将定义为耐受性OPC而没有任何立即不良反应。
|
长达2周
|
|
接受OPC的患者,接受或处方阿莫西林或第一代头孢菌素的患者比例
大体时间:第一天
|
第一天
|
|
|
基于同意OPC的合格参与者的比例
大体时间:长达2周
|
长达2周
|
|
|
基于过敏风险评估和OPC的持续时间的可行性(使用CRF时间戳计算)
大体时间:长达2周
|
长达2周
|
|
|
患者和护理人员对BLA和OPC的看法
大体时间:第一天
|
在完成口头挑战之后,参与者及其护理人员将填写一份研究问卷,以评估他们对口腔挑战安全性的看法及其对使过敏标签从图表中删除的看法。
|
第一天
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.